Cowen & Co. Keeps Their Hold Rating on Chimerix

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Chimerix (NASDAQ: CMRX) today and set a price target of $6. The company’s shares opened today at $4.77.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 11.3% and a 49.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.

Chimerix has an analyst consensus of Hold, with a price target consensus of $8.

Find more picks by Best Performing Analysts >>

Based on Chimerix’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $19.24 million. In comparison, last year the company had a GAAP net loss of $17.75 million.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMRX in relation to earlier this year. Most recently, in March 2018, Michelle Berrey, the President & CEO of CMRX bought 10,071 shares for a total of $42,902.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Chimerix, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.